- ICH GCP
- Registr klinických studií v USA
- Klinická studie NCT07637669
Olfactory Function and Model-Based Behavior in People Living With HIV and SUD
Olfactory Function and Model-based Behavior in People Living With HIV and SUD
Background:
Human immunodeficiency virus (HIV) infection can affect areas of the brain that control thinking ability. These same areas of the brain also control the sense of smell. HIV infection is common in people with substance use disorder (SUD). SUD also affects thinking ability. Researchers want to learn more about the connection between the sense of smell and decision-making ability in people with HIV, SUD, or both.
Objective:
To test the sense of smell in people with HIV and/or SUD and how they make choices based on odors.
Eligibility:
People aged 18 to 65 years with any of these: (1) HIV, (2) SUD, (3) both HIV and SUD, or (4) neither SUD nor HIV.
Design:
Participants will have 2 visits. Each visit will last 3 to 5 hours.
In visit 1, participants will have a blood draw and a saliva swab. They will answer questions about their health, sleep habits, food intake, and substance use. They will have smell tests:
They will smell scented sticks and answer questions about them. They will be blindfolded for some tests.
They will perform tasks on a computer. They will look at pictures and smell pleasant food odors, such as chocolate cake or pizza. Smells will be delivered using a nasal mask. Their sniffing and breathing will be measured. They may also be exposed to odor-free air. They will eat food that corresponds to one of the food odors they smelled.
In visit 2, participants will do a saliva swab and a different computer task that involves odors. They will also have tests of their attention and memory. Participants may opt to have an imaging scan of the brain.
Přehled studie
Postavení
Podmínky
Detailní popis
Study Description:
Cognitive impairments persist in people living with Human Immunodeficiency Virus (HIV) despite anti-retroviral therapy (ART). However, these impairments remain under-characterized and it is not clear whether they include deficits in model-based control of behavior. HIV is common in people with substance use disorder (SUD) but the combined impact of HIV and SUD on cognition remains unclear. The olfactory system is uniquely vulnerable to neurodegeneration and overlaps with brain regions involved in decision making. This study will investigate olfactory function and model-based behavior in people living with HIV and SUD, and relate these measures to biomarkers of neurodegeneration.
Objectives:
The primary objective of this protocol is to compare olfactory function and performance on behavioral tasks assessing model-based behavior between people living with and without HIV, and between people with and without SUD.
Secondary objectives of this protocol are to compare blood-based and MRI0-based biomarkers of neurodegeneration between people living with and without HIV, and between people with and without SUD.
Endpoints:
Primary:
- Olfactory function (Sniffin Sticks Threshold, Discrimination, and Identification tests)
- Behavior on tasks assessing model-based behavior (outcome devaluation and sensory preconditioning)
Secondary:
- Blood-based biomarker of neurodegeneration (Neurofilament Light Chain [NfL])
- MRI-based biomarker of neurodegeneration (Magnetic Resonance Imaging)
Typ studie
Zápis (Odhadovaný)
Kontakty a umístění
Studijní kontakt
- Jméno: NIDA IRP Screening Team
- Telefonní číslo: (800) 535-8254
- E-mail: researchstudies@nida.nih.gov
Studijní záloha kontaktů
- Jméno: Thorsten Kahnt, Ph.D.
- Telefonní číslo: (667) 312-5175
- E-mail: thorsten.kahnt@nih.gov
Studijní místa
-
-
Maryland
-
Baltimore, Maryland, Spojené státy, 21224
- National Institute on Drug Abuse
-
Kontakt:
- Thorsten Kahnt
- Telefonní číslo: 667-312-5175
- E-mail: thorsten.kahnt@nih.gov
-
-
Kritéria účasti
Kritéria způsobilosti
Věk způsobilý ke studiu
- Dospělý
- Starší dospělý
Přijímá zdravé dobrovolníky
Metoda odběru vzorků
Studijní populace
Popis
- INCLUSION CRITERIA:
In order to be eligible to participate in this study, an individual must meet all of the following criteria:
For all participants:
- Stated willingness to comply with all study procedures and availability for the duration of the study
- Aged 18-65 years old. Justification: prevalence of olfactory impairments increases with age; after age 53, the prevalence is 24.5 percent, increasing to 62.5 percent in people ages 80-97.
- Agreement to adhere to Lifestyle Considerations throughout study duration.
- Ability of subject to understand and the willingness to sign a written informed consent document.
For participants in the HIV+ and SUD+ and HIV+ and SUD- groups:
-HIV positive.
For participants in the HIV+ and SUD+ and HIV- & SUD+ groups:
-Substance Use Disorder (SUD) other than Alcohol Use Disorder (AUD) or Tobacco Use Disorder (TUD).
EXCLUSION CRITERIA:
An individual who meets any of the following criteria will be excluded from participation in this study:
For all participants:
- History of neurological illnesses or neurosurgery including but not limited to cerebrovascular accident, Parkinson disease, Alzheimer disease, Huntington disease, central nervous system (CNS) tumor, significant head trauma with sequelae, multiple sclerosis or other demyelinating diseases, epilepsy, movement disorders. The MAI will also retain discretion to exclude based on a history of a neurological illness or trauma that may compromise data integrity.
- History of current (past 12 months) uncontrolled major DSM-5 psychiatric disorder including major affective disorder, obsessive-compulsive disorder, schizophrenia, or posttraumatic stress disorder, excluding SUD.
- Candidates who recently (12 hours prior to a study visit) used medications and/or substances that are psychoactive or otherwise affect alertness will have to pass a clinical assessment for intoxication on the day of the study visit. Based on participant preferences and MAI/PI judgment, participants who fail the clinical assessment for intoxication will either be withdrawn or rescheduled.
- History of clinically significant anaphylaxis, e.g., due to severe asthma or food and nonfood allergies (e.g., latex, detergents, soap, etc.). The MAI will retain discretion to exclude a participant based on this criterion.
- Uncorrected impairments in visual acuity.
- Non-English speaking. Justification: The data integrity of some of the behavioral tasks used in this study would be compromised as they have only been validated in English.
- Pregnancy.
- Any other condition that in the judgment of the investigators is incompatible with participation.
For participants in the HIV+ and SUD- and HIV- and SUD- groups:
- History of current (past 12 months) SUD, excluding tobacco use disorder.
- Pattern of alcohol and drug use in the past 12 months that is indicative of harmful use, loss of control over use, or physical dependence.
- Daily alcohol or drug use (excluding caffeine and nicotine) for at least 4 continuous weeks in the past 12 months.
For participants in the HIV- and SU+ and HIV- and SUD- groups:
-HIV positive.
For the Optional MRI Segment:
-Unable to undergo MRI scanning due to certain metallic or magnetic devices or implants in the body, or claustrophobia.
Studijní plán
Jak je studie koncipována?
Detaily designu
Kohorty a intervence
Skupina / kohorta |
|---|
|
HIV- & SUD-
Individuals without HIV and without an SUD
|
|
HIV- & SUD+
Individuals without HIV and with an SUD
|
|
HIV+ & SUD-
Individuals with HIV and without an SUD
|
|
HIV+ & SUD+
Individuals with HIV and with an SUD
|
Co je měření studie?
Primární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Olfactory function
Časové okno: Visit 1
|
Sniffin Sticks Threshold, Discrimination, and Identification tests
|
Visit 1
|
|
Model-based decision making
Časové okno: Visit 1 & 2
|
Model-based decision making as assessed in an outcome devaluation task (visit 1) and sensory preconditioning task (visit 2)
|
Visit 1 & 2
|
Sekundární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Neurofilament Light Chain
Časové okno: Visit 1
|
Plasma levels of neurofilament light chain [NfL]
|
Visit 1
|
|
MRI
Časové okno: Visit 2 (optional)
|
MRI-based biomarkers of neurodegeneration
|
Visit 2 (optional)
|
Spolupracovníci a vyšetřovatelé
Vyšetřovatelé
- Vrchní vyšetřovatel: Thorsten Kahnt, Ph.D., National Institute on Drug Abuse (NIDA)
Termíny studijních záznamů
Hlavní termíny studia
Začátek studia (Odhadovaný)
Primární dokončení (Odhadovaný)
Dokončení studie (Odhadovaný)
Termíny zápisu do studia
První předloženo
První předloženo, které splnilo kritéria kontroly kvality
První zveřejněno (Aktuální)
Aktualizace studijních záznamů
Poslední zveřejněná aktualizace (Aktuální)
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
Naposledy ověřeno
Více informací
Termíny související s touto studií
Klíčová slova
Další relevantní podmínky MeSH
Další identifikační čísla studie
- 10002591
- 002591-DA
Plán pro data jednotlivých účastníků (IPD)
Plánujete sdílet data jednotlivých účastníků (IPD)?
Popis plánu IPD
Časový rámec sdílení IPD
Kritéria přístupu pro sdílení IPD
Informace o lécích a zařízeních, studijní dokumenty
Studuje lékový produkt regulovaný americkým FDA
Studuje produkt zařízení regulovaný americkým úřadem FDA
Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .
Klinické studie na HIV
-
Duke UniversityGilead SciencesNáborPrevence HIV | Pre-expoziční profylaxe HIV | Program prevence HIV | Prevence a péče o HIV | Pre-expoziční profylaxe HIVSpojené státy
-
Federal University of São PauloGilead SciencesDokončeno
-
University of Alabama at BirminghamMobile County Health Deparment; Alabama Department of Public HealthNáborHIV | Testování HIV | HIV vazba na péči | Léčba HIVSpojené státy
-
Institute of HIV Research and Innovation Foundation...National Institutes of Health (NIH)NáborPrevence HIV | Dodržování PrEP | HIV Související StigmaThajsko
-
University of Alabama at BirminghamNational Institute of Mental Health (NIMH)NáborPřípravka | HIV | Prevence HIV | Vychytávání PrEPSpojené státy
-
Massachusetts General HospitalNational Institute of Mental Health (NIMH)NáborProveditelnost | Prevence HIV | Vychytávání PrEP | Přijatelnost | Samotestování HIV | Muž partneři HIV-negativní poporodní ženyJižní Afrika
-
ANRS, Emerging Infectious DiseasesHopital Universitaire Robert-Debre; Institut de Recherche pour le Developpement a další spolupracovníciNeznámýHIV | Děti neinfikované HIV | Děti vystavené HIVKamerun
-
University of MinnesotaStaženoHIV infekce | HIV/AIDS | Hiv | AIDS | Problém AIDS/Hiv | AIDS a infekceSpojené státy
-
French National Agency for Research on AIDS and...Elizabeth Glaser Pediatric AIDS FoundationDokončenoPartnerské HIV testování | Poradenství pro pár HIV | Párová komunikace | Výskyt HIVKamerun, Dominikánská republika, Gruzie, Indie
-
University of PennsylvaniaNational Institute of Mental Health (NIMH); University of BotswanaNáborTěhotenství | HIV | Po porodu | Adherence HIV antiretrovirové terapie (ART).Botswana